Advertisement
Joining the Helix BioPharma board is Professor Slawomir Majewski, Head ofthe Department of Dermatology and Venereology at the Warsaw School of Medicinein Poland. Professor Majewski's extensive experience in the field ofdermatology, and especially sexually transmitted diseases and skin cancer,will be of great benefit to the Board of Directors and the senior managementteam at Helix.
Advertisement
Retiring from Helix's board are Conor Gunne and Dr. Richard Rossman, whoserved as directors of Helix for a number of years. "I would like topersonally thank both Conor and Richard for their valuable contribution to theCompany over the many years and wish them both well in their other endeavors,"said Don Segal, CEO of Helix BioPharma.
Helix's management would also like to thank its shareholders for theircontinued support, and looks forward to the further development of theCompany's new drug products, Topical Interferon Alpha-2b and L-DOS47, in theyear ahead.
A Report of Voting Results in respect of the Meeting will be posted on theSEDAR website at (www.sedar.com).
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in thefield of cancer therapy. The company is actively developing innovativeproducts for the prevention and treatment of cancer based on its proprietarytechnologies. Helix's product development initiatives include its TopicalInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listedon the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munichand Stuttgart Stock Exchanges under the same symbol.
The Toronto Stock Exchange has not reviewed and does not acceptresponsibility for the adequacy or accuracy of the content of this NewsRelease. This News Release contains forward-looking statements regarding thedevelopment of the Company's drug products, which statements can be identifiedby the words "looks forward, "development" and "developing". Actual results orevents could differ materially from these forward-looking statements andinformation due to numerous factors, including without limitation, research &development risks, intellectual property risks; product liability risks; therisk of unanticipated expenses, the need for regulatory approvals which is notassured; the need for clinical trials and uncertainty whether they will occuror will be successful; and possible changes in business strategy or plans.These and other risks and uncertainties are contained in Helix's latest AnnualInformation Form at www.sedar.com. Forward-looking statements and informationare based on the assumptions and expectations of Helix's management at thetime they are made, and Helix does not assume any obligation, except asrequired by law, to update any forward-looking statement or information shouldthose assumptions or expectations, or other circumstances change.
SOURCE Helix BioPharma Corp.
